Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Burcin Fraser

Allergy Chevy Chase, MD Medical Doctor

NPI 1548444078 CMS profile 297527

8401 Connecticut Ave Ste 220, Chevy Chase, MD 20815

Open in the dashboard

General payments

$6,521

297 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Burcin Fraser of Chevy Chase, MD is reported in the CMS Open Payments database as having received $6,521 across 297 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,589 65
2024 General $1,150 48
2023 General $850 41
2022 General $602 29
2021 General $711 36
2020 General $870 44
2019 General $749 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Burcin Fraser
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Burcin Fraser were reported at $1,589. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Burcin Fraser Allergy median Middle half National median
2019 $749 $506 $151–$1,337 $163
2020 $870 $409 $108–$1,162 $114
2021 $711 $549 $125–$1,485 $132
2022 $602 $666 $161–$1,594 $149
2023 $850 $780 $186–$1,916 $160
2024 $1,150 $1,031 $271–$2,196 $164
2025 $1,589 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,007 57 payments
  2. Regeneron Healthcare Solutions, Inc. $814 31 payments
  3. AstraZeneca Pharmaceuticals LP $729 39 payments
  4. Genzyme Corporation $717 27 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $511 19 payments
  6. kaleo, Inc. $345 14 payments
  7. Pfizer Inc. $279 15 payments
  8. Genentech USA, Inc. $268 11 payments
  9. Grifols USA, LLC $204 9 payments
  10. OptiNose US, Inc. $184 10 payments
  11. Other $1,462 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,465 294 payments
  2. Consulting Fee $41 2 payments
  3. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $1,158 44 payments
  2. DUPIXENT Inflammation And Immunology $657 25 payments
  3. CUVITRU $545 22 payments
  4. NUCALA $449 22 payments
  5. TRELEGY ELLIPTA $431 27 payments
  6. AUVI-Q $304 12 payments
  7. Xolair $268 11 payments
  8. Xhance $184 10 payments
  9. Xembify $184 8 payments
  10. AIRSUPRA $181 9 payments
  11. Other $3,379 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$12,621

Medicare's payments for the services billed

Medicare patients

28

Average age 72

Services billed

862

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 61%
High blood pressure 54%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $224
  • GENZYME CORPORATION $81
$305 — —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $125
$125 — —
NUCALA
  • GlaxoSmithKline, LLC. $98
$98 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $54
  • Amgen Inc. $26
$80 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $77
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

297 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record